GranuFlo is an acid concentrate made for use in hemodialysis treatment. Hemodialysis treatment helps filter blood for patients who suffer from renal failure of kidney disease. GranuFlo is manufactured by FMC (Fresenius Medical Care), the largest manufacturer of kidney dialysis products and services. Fresenius Medical Care owns a total of 1,800 clinics which used GranuFlo and its sister drug NaturaLyte in hemodialysis treatment.
Since the release of GranuFlo, adverse events were reported from users and clinics administering hemodialysis treatment using the either GranuFlo or NaturaLyte. Since the increased heart attack risk was uncovered, legal action has been pursued against Fresenius Medical Care (FMC) by patients and surviving family members who either suffered a heart attack or lost a loved one to a GranuFlo heart attack. Dialysis lawsuits have also tracked other adverse effects caused by improper administration of GranuFlo.
What is a Heart Attack?
A heart attack occurs when a coronary artery suddenly becomes blocked. During a heart attack, the blockage of the artery prevents the heart muscle from receiving an adequate supply of oxygenated blood. As a result, cells within the heart muscle become damaged and their function becomes impaired. Severe cases of blockage can cause the death of heart muscle cells.
What Are the Symptoms of a GranuFlo Heart Attack?
If you believe that you are suffering from the symptoms of a heart attack, please call 911 immediately and seek out the assistance of a medical professional.
Contact the office of Frank Charles Miranda, P.A. at 813.254.2637 to pursue your GranuFlo dialysis heart attack lawsuit.